Koitabashi Norimichi, Arai Masashi, Niwano Kazuo, Watanabe Atai, Endoh Michiko, Suguta Masahiko, Yokoyama Tomoyuki, Tada Hiroshi, Toyama Takuji, Adachi Hitoshi, Naito Shigeto, Oshima Shigeru, Nishida Takashi, Kubota Satoshi, Takigawa Masaharu, Kurabayashi Masahiko
Department of Medicine and Biological Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
Eur J Heart Fail. 2008 Apr;10(4):373-9. doi: 10.1016/j.ejheart.2008.02.011. Epub 2008 Mar 11.
Connective tissue growth factor (CTGF) has been recently reported as a mediator of myocardial fibrosis; however, the significance of plasma CTGF concentration has not been evaluated in patients with heart failure. The aim of this study was to investigate the clinical utility of plasma CTGF concentration for the diagnosis of heart failure.
We evaluated fifty-two patients with chronic heart failure. The plasma concentration of CTGF and other markers of fibrosis were assessed and compared with clinical and echocardiographic data. Plasma CTGF was significantly elevated in symptomatic patients in proportion to their NYHA classes and was significantly correlated with plasma brain natriuretic peptide (BNP) concentration (r=0.395, P<0.01). Plasma CTGF was also correlated with plasma transforming growth factor beta (TGF-beta) (r=0.512, P<0.01), matrix metalloproteinase (MMP)-2 (r=0.391, P<0.05) and tissue inhibitor of MMP (TIMP)-2 (r=0.354, P<0.05) concentrations. Interestingly, plasma CTGF was correlated with E/E' value evaluated by tissue Doppler echocardiography (r=0.593, P=0.012), but not with systolic function and left ventricular mass.
Our study suggests that plasma CTGF concentration is a novel diagnostic marker for cardiac dysfunction and may provide additional specific information about myocardial fibrosis in chronic heart failure patients.
结缔组织生长因子（CTGF）最近被报道为心肌纤维化的介质；然而，血浆CTGF浓度在心力衰竭患者中的意义尚未得到评估。本研究的目的是探讨血浆CTGF浓度在心力衰竭诊断中的临床应用价值。
我们评估了52例慢性心力衰竭患者。评估了CTGF的血浆浓度和其他纤维化标志物，并与临床和超声心动图数据进行比较。有症状患者的血浆CTGF水平随纽约心脏协会（NYHA）分级显著升高，且与血浆脑钠肽（BNP）浓度显著相关（r = 0.395，P < 0.01）。血浆CTGF还与血浆转化生长因子β（TGF-β）（r = 0.512，P < 0.01）、基质金属蛋白酶（MMP）-2（r = 0.391，P < 0.05）和MMP组织抑制剂（TIMP）-2（r = 0.354，P < 0.05）浓度相关。有趣的是，血浆CTGF与组织多普勒超声心动图评估的E/E'值相关（r = 0.593，P = 0.012），但与收缩功能和左心室质量无关。
我们的研究表明，血浆CTGF浓度是心脏功能障碍的一种新型诊断标志物，可能为慢性心力衰竭患者的心肌纤维化提供额外的特异性信息。
